101 related articles for article (PubMed ID: 10732712)
1. IL-2 gene-modified tumour vaccines: monitoring of IL-2 levels in serum and peritoneal cavity of vaccinated mice.
Indrová M; Pajtasz-Piasecka E; Jandlová T; Símová J; Bubeník J; Radzikowski C
Folia Biol (Praha); 1999; 45(1):7-11. PubMed ID: 10732712
[TBL] [Abstract][Full Text] [Related]
2. Irradiation of genetically modified plasmacytoma vaccines results in upregulation of CD80 molecule expression, IL-2 production and higher therapeutic efficacy of the vaccines.
Símová J; Reinis M; Sobota V; Capková J; Bubeník J; Jandlová T
Folia Biol (Praha); 2000; 46(1):11-5. PubMed ID: 10730877
[TBL] [Abstract][Full Text] [Related]
3. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor-producing tumour vaccines.
Rössner P; Bubeník J; Sobota V; Indrová M; Hájková R; Mendoza L; Jandlová T; Símová J
Folia Biol (Praha); 1999; 45(5):173-7. PubMed ID: 10730885
[TBL] [Abstract][Full Text] [Related]
5. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy of plasmacytoma: comparison of the therapeutic efficacy of tumour cells transduced with the interleukin-2, interleukin-4, or interleukin-6 genes.
Bubeník J; Símová J; Zeuthen J; Diamant M; Jandlová T; Bubeníková D
Folia Biol (Praha); 1994; 40(1-2):29-36. PubMed ID: 7958062
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral IL-12 gene transfer improves the therapeutic efficacy of IL-12 but not IL-19.
Sobota V; Bubeník J; Símová J; Jandlová T
Folia Biol (Praha); 2000; 46(5):191-3. PubMed ID: 11055798
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of the kinesis of immune responses in mice vaccinated by different kinds of recombinant hepatitis B vaccines].
Hu ZY; He P; Fang X; Qiu SH; Liang ZL; Li HM; Zhuang H
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):810-4. PubMed ID: 19103120
[TBL] [Abstract][Full Text] [Related]
10. IL-2 gene transfer in immunotherapy of cancer: local administration of IL-2-activated lymphocytes and X63-m-IL-2 cells constitutively producing IL-2 inhibits growth of plasmacytomas in syngeneic mice.
Bubeník J; Lotzová E; Indrová M; Simová J; Jandlová T; Savary CA
Nat Immun Cell Growth Regul; 1991; 10(5):247-55. PubMed ID: 1758466
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy of cancer: use of IL-2 gene transfer and kinetics of local T and NK cell subsets.
Bubeník J; Zeuthen J; Bubeníková D; Símová J; Jandlová T
Anticancer Res; 1993; 13(5A):1457-60. PubMed ID: 8239520
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
13. [Immunization with targeted fusion anticaries DNA vaccine via intramuscular route:experiment with murine].
Yu F; Fan MW; Xu QA; Jia R; Guo JH; Bian Z; Chen Z; Peng B; Fan B
Zhonghua Yi Xue Za Zhi; 2004 May; 84(9):754-9. PubMed ID: 15200917
[TBL] [Abstract][Full Text] [Related]
14. Irradiated IL-2 gene-modified plasmacytoma vaccines are more efficient than live vaccines.
Símová J; Bubeník J; Jandlová T; Indrová M
Int J Oncol; 1998 May; 12(5):1195-8. PubMed ID: 9538149
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interleukin-2 acts as an adjuvant and helps to increase the efficacy of tumour vaccines.
Vondrys P; Símová J; Takácová S; Jandlová T; Bubeník J
Folia Biol (Praha); 1997; 43(1):39-40. PubMed ID: 9158948
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells.
Ogawa F; Iinuma H; Okinaga K
Scand J Immunol; 2004 May; 59(5):432-9. PubMed ID: 15140052
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice.
Kircheis R; Küpcü Z; Wallner G; Rössler V; Schweighoffer T; Wagner E
Cancer Gene Ther; 2000 Jun; 7(6):870-8. PubMed ID: 10880017
[TBL] [Abstract][Full Text] [Related]
20. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y
Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
